Verrica Pharmaceuticals Inc. (VRCA)

7.26 +0.50 (+7.40%) At close: 04:00PM EDT

Verrica Pharmaceuticals Inc.

44 West Gay Street
Suite 400
West Chester, PA 19380
United States
484 453 3300
https://www.verrica.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 100

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Ted White	President, CEO & Director	914.68k	N/A	1965
Mr. Christopher G. Hayes	Chief Legal Officer, Secretary, Chief Compliance Officer & General Counsel	607.38k	N/A	1964
Mr. Joe Bonaccorso	Chief Commercial Officer	635.38k	N/A	1964
Mr. P. Terence Kohler	Chief Financial Officer	N/A	N/A	N/A
Dr. Gary Goldenberg M.D.	Chief Medical Officer	553.03k	N/A	1977
Mr. Eugene Scavola	Executive Vice President of Technical Operations	N/A	N/A	N/A
Dr. Bradley J. Catalone MBA, Ph.D.	Head of Drug Development	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Verrica Pharmaceuticals Inc., a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts. The company also develops VP-315, an oncolytic peptide-based injectable therapy, which is in phase II clinical trial for the treatment of dermatology oncologic conditions which includes basal cell carcinoma; and VP-103, a cantharidin-based product candidate for the treatment of plantar warts and is in phase II clinical trial. In addition, it offers YCANTH for the treatment of molluscum contagiosum. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, such as non-metastatic melanoma and non-metastatic merkel cell carcinoma. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.

Corporate governance

Verrica Pharmaceuticals Inc.’s ISS governance QualityScore as of 1 May 2024 is 9. The pillar scores are Audit: 9; Board: 10; Shareholder rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.